You are here

GSK

GSK posts mixed survival data for Jemperli/Zejula combo in first-line ovarian cancer

BioSpace

Fri, 12/20/24 - 11:24 am

clinical trials

GSK and Muna Therapeutics partner to develop new treatments for Alzheimer’s

Biopharma Reporter

Tue, 12/10/24 - 11:33 am

Muna Therapeutics

Alzheimer's disease

GSK pens $45M Relation-ship with AI biotech to identify fibrotic, osteoarthritis targets

Fierce Biotech

Tue, 12/10/24 - 10:44 am

artificial intelligence

fibrotic diseases

ASH: With survival win against J&J's Darzalex, GSK bolsters case for return of myeloma ADC Blenrep

Fierce Pharma

Mon, 12/9/24 - 09:10 pm

Multiple Myeloma

GSK inks 2nd neuro pact in weeks, this time with Danish biotech Muna in Alzheimer's

Fierce Biotech

Thu, 12/5/24 - 11:49 am

Muna Therapeutics

Alzheimer's disease

GSK cuts Shingrix deliveries in revised Zhifei China pact, moves closer to RSV vaccine deal

Fierce Pharma

Thu, 12/5/24 - 11:39 am

GSK goes East again, snagging option on preclinical DualityBio ADC for $30M

Fierce Biotech

Wed, 12/4/24 - 10:58 am

antibody-drug conjugates

GSK taps Rgenta to develop new RNA-targeting treatments, offering up to $500M per target

Fierce Biotech

Wed, 12/4/24 - 10:42 am

Rgenta Therapeutics

GSK scratches itch for phase 3 win, hitting goal in liver disease trial to open up untapped market

Fierce Biotech

Tue, 11/19/24 - 11:18 am

clinical trials

GSK hails survival data with revived myeloma drug Blenrep

Pharmaphorum

Thu, 11/14/24 - 10:03 am

Multiple Myeloma

clinical trials

GSK launches gynecological cancer initiative after survey reveals care gaps

Medical Marketing and Media

Tue, 11/12/24 - 08:46 pm

gynecological cancers

GSK partners with Flagship startup to hunt for Parkinson’s drugs

BioPharma Dive

Tue, 11/12/24 - 08:43 pm

Vesalius Therapeutics

Parkinson's Disease

GSK calls it quits on trade group BIO for 2025, following exits by Takeda, UCB and more

Fierce Pharma

Sun, 11/10/24 - 09:33 pm

GSK CEO addresses declining trust in vaccines following Trump re-election

Clinical Trials Arena

Thu, 11/7/24 - 11:26 am

GSK’s RSV vaccine approved in Canada for adults aged 50 to 59

Pharmaceutical Technology

Wed, 11/6/24 - 08:04 pm

GSK axes vaccine from $2.1B deal, switching to preclinical successor over 'increased competition'

Fierce Biotech

Thu, 10/31/24 - 09:37 am

pneumococcal disease

GSK tries to steady the ship as Arexvy sales plummet in wake of CDC guidance changes

Fierce Pharma

Wed, 10/30/24 - 11:47 am

GSK to pay $300M to license drug it sees as potential lupus treatment

BioPharma Dive

Tue, 10/29/24 - 11:38 am

GSK plans $800m US manufacturing investment

Pharmaphorum

Fri, 10/25/24 - 11:05 am

drug manufacturing

GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults

Fierce Pharma

Thu, 10/24/24 - 10:58 am

Pages